Clinical Scorecard: Subclinical Eye Changes in Graves' Disease: Introducing the FUMO Score as a Predictive Tool for Progression of Graves' Orbitopathy
At a Glance
Category
Detail
Condition
Graves' orbitopathy (GO) in Graves' disease (GD)
Key Mechanisms
Autoimmune targeting of TSH receptor and orbital fibroblasts causing soft tissue inflammation, glycosaminoglycan production, and adipose tissue expansion
Target Population
Patients with newly diagnosed Graves' disease without overt Graves' orbitopathy
Care Setting
Endocrinology and ophthalmology outpatient clinics for early risk stratification and monitoring
Key Highlights
The FUMO score combines visual function tests and orbital ultrasound to predict GO progression with high accuracy (AUC=0.84).
Medium-high FUMO scores (3-8) correlate with increased risk of developing active and moderate-to-severe GO within 24 months.
TRAb levels, FT3 levels, and smoking status independently increase GO risk alongside the FUMO score.
Guideline-Based Recommendations
Diagnosis
Perform baseline ophthalmological evaluation including visual function tests and orbital ultrasound in GD patients without GO.
Calculate the FUMO score (0-8) to stratify patients into low (0-2) or medium-high (3-8) risk groups for GO development.
Management
Consider closer follow-up and early intervention in medium-high risk patients to monitor and potentially prevent GO progression.
Favor antithyroid drugs or total thyroidectomy over radioactive iodine in high-risk patients to reduce GO worsening risk.
Consider prophylactic selenium supplementation in mild GO cases to prevent disease worsening.
Monitoring & Follow-up
Regularly assess ocular signs and symptoms in GD patients, especially those with medium-high FUMO scores.
Monitor TRAb and FT3 levels as they are independent predictors of GO progression.
Risks
Smoking increases the risk of GO development and severity; smoking cessation should be advised.
Radioactive iodine therapy may exacerbate GO in high-risk patients.
Patient & Prescribing Data
Patients with newly diagnosed Graves' disease without clinical signs of GO
FUMO score combined with TRAb and FT3 levels helps identify patients who may benefit from tailored hyperthyroidism treatment and preventive strategies to reduce GO risk.
Clinical Best Practices
Use the FUMO score for early risk stratification of GO in GD patients without overt eye disease.
Incorporate smoking status and thyroid antibody levels in risk assessment models.
Implement multidisciplinary care involving endocrinologists and ophthalmologists for comprehensive management.
Avoid radioactive iodine in patients at medium-high risk of GO progression.
Educate patients on the importance of smoking cessation and adherence to follow-up.
by Giulia Lanzolla, Francesca Saba, Silvia Corrias, Filippo Lixi, Giulia Faa, Alessandro Colleo, Chiara Mura, Gian Luigi Canu, Federico Cappellacci, Alberto Cuccu, Giuseppe Giannaccare, Stefano Mariotti, Francesco Boi
